| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2020 |
| Year reshoring implemented or to be implemented: | 2020 |
| Domestically, the work will be done: | In-house |
| City reshored to: | Myford |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals, Biotechnology |
| Product(s) reshored | commercial biologics API, small molecules |
| What non-domestic negative factors made offshoring less attractive? | Strained offshore relationships, Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Impact on domestic economy, Lead time/Time to market, Proximity to customers/market, Other, Covid-19 |
